Gaedke and colleagues (Gaedcke et al., 2010) demonstrated that in 94 patients with LARC, tumors bearing a Gly12Val mutation were related to significantly higher rates of tumor regression than those with a Gly13Asp mutation, despite the overall presence of KRAS mutations did not correlate with tumor response and patient's outcome after preoperative chemoradiotherapy. The gene discussed is KRAS; the disease is neoplasm.